Histogen Inc

NASDAQ:HSTO   3:58:07 PM EDT
0.90
+0.06 (+7.07%)
4:01:47 PM EDT: $0.90 0.00 (-0.42%)
Products

Histogen And Amerimmune Announce Positive Top-Line Study Results From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients

Published: 06/22/2021 12:36 GMT
Histogen Inc (HSTO) - Ric:ammmm.
Ul]:histogen and Amerimmune Announce Positive Top-line Study Results From Its Phase 1 Study of Emricasan in Mild Symptomatic Covid-19 Patients.
Histogen Inc - Emricasan Found to Be Safe and Well Tolerated With No Serious Adverse Events.
Histogen -patients Completing Emricasan Treatment Had Complete Resolution of Symptoms Commonly Associated in Mild Covid-19 at Day 7 Continuing to Day 45.